Literature DB >> 20622742

Cisplatin-induced renal salt wasting syndrome.

Tamim Hamdi1, Shadi Latta, Bassel Jallad, Fayez Kheir, Mohamad N Alhosaini, Ashok Patel.   

Abstract

Cisplatin was the first platinum compound to be introduced as a chemotherapeutic agent with antineoplastic activity against a wide variety of solid tumors. Renal impairment with a decline in glomerular filtration has been the classical nephrotoxicity of cisplatin. Renal salt wasting syndrome is yet another, though it is not common. Previous studies were identified by searching the Pubmed database using the following keywords: cisplatin, cisplatin nephrotoxicity, renal salt wasting, and salt loosing nephropathy. Renal salt wasting syndrome has been described in 17 case reports since 1984. It is a rare side effect of cisplatin that manifests with polyuria, hypovolemia, and hyponatremia, and, because of similarities in clinical settings and laboratory values, it is frequently misdiagnosed as a syndrome of inappropriate antidiuretic hormone. Other causes of polyuria and hyponatremia should be excluded. Treatment aims at restoring the lost water and salt. Substituting cisplatin with carboplatin depends on individual clinical settings. Prognosis is excellent, as recovery was the rule in all the reported cases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20622742     DOI: 10.1097/SMJ.0b013e3181e63682

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  15 in total

Review 1.  Clinical salt deficits.

Authors:  Friedrich C Luft
Journal:  Pflugers Arch       Date:  2014-12-05       Impact factor: 3.657

2.  Severe Hyponatremia Due to Cisplatin-induced Syndrome of Inappropriate Secretion of Antidiuretic Hormone.

Authors:  Haisam Abid; Nadir Siddiqui; Rosana Gnanajothy
Journal:  Cureus       Date:  2019-08-22

Review 3.  Diagnosis and management of hyponatremia in cancer patients.

Authors:  Jorge J Castillo; Marc Vincent; Eric Justice
Journal:  Oncologist       Date:  2012-05-22

Review 4.  Hyponatraemia: more than just a marker of disease severity?

Authors:  Robert W Schrier; Shailendra Sharma; Dmitry Shchekochikhin
Journal:  Nat Rev Nephrol       Date:  2012-11-20       Impact factor: 28.314

5.  Cisplatin-induced syndrome of inappropriate antidiuretic hormone secretion (SIADH) with life-threatening hyponatraemia.

Authors:  Aaron C Tan; Gavin M Marx
Journal:  BMJ Case Rep       Date:  2018-01-31

6.  Science behind cisplatin-induced nephrotoxicity in humans: a clinical study.

Authors:  P A Arunkumar; G L Viswanatha; N Radheshyam; H Mukund; M S Belliyappa
Journal:  Asian Pac J Trop Biomed       Date:  2012-08

7.  Capillary rarefaction is more closely associated with CKD progression after cisplatin, rhabdomyolysis, and ischemia-reperfusion-induced AKI than renal fibrosis.

Authors:  Anna Menshikh; Lauren Scarfe; Rachel Delgado; Charlene Finney; Yuantee Zhu; Haichun Yang; Mark P de Caestecker
Journal:  Am J Physiol Renal Physiol       Date:  2019-09-11

8.  Hyponatremia in patients with esophageal cancer treated with chemotherapy including cisplatin.

Authors:  Ayako Shimada; Hiroya Takeuchi; Kazumasa Fukuda; Koichi Suda; Rieko Nakamura; Norihito Wada; Hirofumi Kawakubo; Yuko Kitagawa
Journal:  Esophagus       Date:  2018-04-27       Impact factor: 4.230

9.  Cisplatin-induced hyponatremia in malignancy: comparison between brand-name and generic formulation.

Authors:  Nobuaki Ochi; Hiromichi Yamane; Katsuyuki Hotta; Hiromi Fujii; Hideko Isozaki; Yoshihiro Honda; Tomoko Yamagishi; Toshio Kubo; Mitsune Tanimoto; Katsuyuki Kiura; Nagio Takigawa
Journal:  Drug Des Devel Ther       Date:  2014-12-03       Impact factor: 4.162

Review 10.  Molecular and physical technologies for monitoring fluid and electrolyte imbalance: A focus on cancer population.

Authors:  Devasier Bennet; Yasaman Khorsandian; Jody Pelusi; Amy Mirabella; Patrick Pirrotte; Frederic Zenhausern
Journal:  Clin Transl Med       Date:  2021-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.